These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 29532156)
1. Beta-blockers do not protect against cardiac toxicity of hyperkalemia : Response to the article by Legrand et al. 'Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications' [1]. de Tymowski C; Atchade E; Montravers P; Provenchère S Clin Res Cardiol; 2018 Sep; 107(9):868-869. PubMed ID: 29532156 [No Abstract] [Full Text] [Related]
2. Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications. Legrand M; Ludes PO; Massy Z; Rossignol P; Parenica J; Park JJ; Ishihara S; AlHabib KF; Maggioni A; Miró Ò; Sato N; Cohen-Solal A; Fairman E; Lassus J; Harjola VP; Mueller C; Peacock FW; Choi DJ; Plaisance P; Spinar J; Kosiborod M; Mebazaa A; Gayat E; Clin Res Cardiol; 2018 Mar; 107(3):214-221. PubMed ID: 29080909 [TBL] [Abstract][Full Text] [Related]
3. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Tamirisa KP; Aaronson KD; Koelling TM Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880 [TBL] [Abstract][Full Text] [Related]
4. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Buysse JM; Huang IZ; Pitt B Future Cardiol; 2012 Jan; 8(1):17-28. PubMed ID: 22185443 [TBL] [Abstract][Full Text] [Related]
5. Hyperkalemia in patients with heart failure: incidence, prevalence, and management. Desai AS Curr Heart Fail Rep; 2009 Dec; 6(4):272-80. PubMed ID: 19948096 [TBL] [Abstract][Full Text] [Related]
6. Life-threatening hyperkalemia in severe heart failure. Chakko SC; Frutchey J; Gheorghiade M Am Heart J; 1989 May; 117(5):1083-91. PubMed ID: 2711969 [TBL] [Abstract][Full Text] [Related]
7. No need for urgent revisiting of kalaemia levels in guidelines despite use of mineralocorticoid receptor antagonists: bring in more evidence. Bayés-Genís A; Lupón J; Núñez J Eur J Heart Fail; 2018 Sep; 20(9):1252-1254. PubMed ID: 30252187 [No Abstract] [Full Text] [Related]
8. Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism. Poggio R; Grancelli HO; Miriuka SG Postgrad Med J; 2010 Mar; 86(1013):136-42. PubMed ID: 20237007 [TBL] [Abstract][Full Text] [Related]
9. Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure. Bakhai A; Palaka E; Linde C; Bennett H; Furuland H; Qin L; McEwan P; Evans M J Med Econ; 2018 Dec; 21(12):1172-1182. PubMed ID: 30160541 [TBL] [Abstract][Full Text] [Related]
10. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD; Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304 [TBL] [Abstract][Full Text] [Related]
12. Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). Khan SS; Campia U; Chioncel O; Zannad F; Rossignol P; Maggioni AP; Swedberg K; Konstam MA; Senni M; Nodari S; Vaduganathan M; Subacius H; Butler J; Gheorghiade M; Am J Cardiol; 2015 Mar; 115(6):790-6. PubMed ID: 25728846 [TBL] [Abstract][Full Text] [Related]
13. Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders. Sarwar CMS; Bhagat AA; Anker SD; Butler J Handb Exp Pharmacol; 2017; 243():537-560. PubMed ID: 28382468 [TBL] [Abstract][Full Text] [Related]
15. Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management. McCullough PA; Beaver TM; Bennett-Guerrero E; Emmett M; Fonarow GC; Goyal A; Herzog CA; Kosiborod M; Palmer BF Rev Cardiovasc Med; 2014; 15(1):11-23. PubMed ID: 24762462 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B; J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881 [TBL] [Abstract][Full Text] [Related]
17. Hyperkalemia in chronic heart failure. Altay H Turk Kardiyol Dern Ars; 2021 Apr; 49(3):178-179. PubMed ID: 33847266 [No Abstract] [Full Text] [Related]
19. To bind or not to bind: potassium-lowering drugs in heart failure. van der Meer P; van Veldhuisen DJ Eur Heart J; 2011 Apr; 32(7):791-2. PubMed ID: 21383002 [No Abstract] [Full Text] [Related]
20. Hyperkalemia: a dangerous diagnosis for patients with congestive heart failure. Ide B; Drew BJ Prog Cardiovasc Nurs; 1997; 12(4):36-7. PubMed ID: 9433734 [No Abstract] [Full Text] [Related] [Next] [New Search]